Proteins serve as the workhorses of the cell, orchestrating complex biological processes essential for life. While the genetic code determines a protein’s initial structure, the story doesn’t end there. After synthesis, proteins undergo a multitude of chemical modifications, collectively known as post-translational modifications, which fine-tune their activity, localization, and interaction with other cellular components. These PTMs act as molecular switches governing critical cellular pathways, and abnormalities in these modifications have profound implications in the onset and progression of many diseases.

Traditional methods to identify PTMs rely heavily on laboratory techniques such as mass spectrometry. While powerful, these methods are laborious, costly, and often require pre-existing knowledge of the modifications being sought. This necessity for prior information hinders the discovery of novel or rare PTMs, limiting our understanding of protein regulation and its link to pathologies. The challenge lies in the vast diversity and complexity of protein modifications, making it difficult to detect changes that were not previously cataloged.

RNovA addresses these limitations through an innovative zero-shot learning approach that does not depend on predefined databases or labeled datasets. By leveraging deep learning architectures trained on vast amounts of peptide sequence data, RNovA can confidently infer the presence of new or atypical modifications in peptides directly from raw mass spectrometry data without the need for prior examples. This open discovery capability allows researchers to identify unexpected PTMs that could escape detection by conventional methods.

The algorithm operates by interpreting mass spectrometry outputs to reconstruct peptide sequences and simultaneously detect modifications through computational modeling. Instead of fitting a puzzle based on known pieces, RNovA creates an adaptive model that predicts modifications in a de novo fashion, enabling researchers to glimpse entire landscapes of cellular changes previously hidden from view. This methodology represents a significant leap forward in proteomics, where the complexity of the proteome has historically been a formidable obstacle.

Beyond its technical novelty, RNovA’s implications for medical research are profound. By expanding the catalog of PTMs, scientists gain new biomarkers that could serve as early indicators of diseases like cancer and neurodegenerative disorders. The ability to rapidly and accurately identify these molecular fingerprints paves the way for innovative diagnostic tools, targeted therapies, and personalized medicine strategies that address the unique biochemical milieu of individual patients.

The research team envisions RNovA as a powerful adjunct to existing laboratory techniques, accelerating the pace of discovery and reducing costs. This democratization of proteomic analysis empowers biologists to explore uncharted territories within cellular biology, fostering interdisciplinary collaboration between computational scientists and experimental biologists.

Moreover, this development signals a broader trend in biomedical sciences where machine learning algorithms enhance our ability to interpret complex biological data. As artificial intelligence continues to evolve, tools like RNovA highlight the potential to unravel intricate biological systems and molecular mechanisms through sophisticated computational frameworks.

Zeping Mao, the PhD candidate who spearheaded this research, emphasizes the transformative potential of this tool: by identifying previously undetectable modifications, RNovA not only supports diagnostic innovation but also broadens the horizon for basic biological research, uncovering fundamental insights into cellular regulation and disease pathology.

Published in the prestigious journal Nature Biotechnology, the paper titled “Zero-Shot De Novo Peptide Sequencing with Open Post-Translational Modification Discovery” details the algorithm’s development, validation, and its potential applications across biomedical research disciplines. This work sets a new standard for computational proteomics, demonstrating the tremendous value of integrating advanced machine learning methodologies to solve longstanding biological challenges.

As this technology moves from research to clinical settings, the promise of earlier disease detection and more precise therapeutic targeting will become increasingly tangible. RNovA represents not just a technical breakthrough but a paradigm shift in how we understand and manipulate the molecular underpinnings of health and disease.

The success of RNovA is a testament to the synergy between computational innovation and biochemical expertise, offering a window into cellular processes that, until now, have been obscured by technical limitations. By opening this window wider, the algorithm changes the landscape of protein science and translational medicine, propelling us toward a future where complex diseases can be understood, detected, and treated with unprecedented sophistication.

Subject of Research: Cells
Article Title: Zero-shot de novo peptide sequencing with open posttranslational modification discovery
News Publication Date: 19-May-2026
Web References: https://doi.org/10.1038/s41587-026-03116-1
References: Mao, Z., et al. (2026). Zero-Shot De Novo Peptide Sequencing with Open Post-Translational Modification Discovery. Nature Biotechnology.
Image Credits: Zeping Mao
Keywords: Artificial intelligence, Life sciences, Diseases and disorders, Machine learning, Human biology, Cell biology, Alzheimer disease, Cancer

The intricate interplay between epigenetic regulation and immune responses has become an intense area of investigation, especially within the context of chronic inflammatory conditions. Here, the researchers focused on histone lactylation, a modification discovered relatively recently that adds lactate groups to histones—a process linking cellular metabolism and gene expression. Their findings suggest that increased histone lactylation modulates macrophage phenotype shifts toward the pro-inflammatory M1 state by activating GLI3, a key transcription factor traditionally connected to developmental signaling pathways.

Macrophages are central players in AAA pathology, where the balance between M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes critically influences disease trajectory. In AAA lesions, M1 macrophage dominance has been associated with exacerbated inflammation and tissue degradation. The elucidation of a histone lactylation-GLI3 axis as a driver of M1 polarization uncovers an epigenetic mechanism linking metabolic cues to inflammatory gene expression programs. This paradigm not only advances our understanding of aneurysm biology but also identifies new potential molecular targets for therapeutic intervention.

An intriguing aspect of this research is the role of exosomes—small extracellular vesicles implicated in cell-to-cell communication—in mediating pathological signaling. The study shows that M1 macrophages, upon GLI3 activation, enhance the release of exosomes enriched with SERPINE1, a serine protease inhibitor known to regulate extracellular matrix remodeling and inflammation. Elevated exosomal SERPINE1 appears to modulate the local vascular microenvironment, facilitating processes that weaken the aortic wall and promote aneurysm expansion.

The implications of identifying exosomal SERPINE1 as a critical effector molecule extend beyond mechanistic insights. Since exosomes can be isolated from bodily fluids, the detection of SERPINE1-enriched vesicles could serve as a minimally invasive biomarker for AAA progression. Moreover, therapeutic strategies aimed at modulating exosome content or inhibiting their release could represent innovative avenues to halt or slow aneurysm growth.

Methodologically, the study applied state-of-the-art epigenomic profiling techniques combined with single-cell RNA sequencing to dissect macrophage heterogeneity and track histone lactylation’s impact at a granular resolution. In vivo experiments using established murine AAA models corroborated the epigenetic findings, demonstrating that pharmacological blockade of lactylation or GLI3 signaling mitigated aneurysm formation and reduced levels of circulating exosomal SERPINE1.

Of critical interest was the metabolic reprogramming observed in aneurysmal macrophages, where elevated glycolysis increased intracellular lactate, fueling histone lactylation reactions. This metabolic-epigenetic axis positions cellular energy metabolism as a central regulator of inflammatory phenotype shifts and extracellular vesicle-mediated cross-talk in vascular disease. Such insights underscore the significance of systemic metabolic health in the etiology and progression of AAA.

The discovery of GLI3’s role outside its classical developmental context marks a notable advance. While GLI transcription factors have been historically studied in hedgehog signaling during embryogenesis, their function in adult inflammatory disorders is only beginning to surface. This study highlights GLI3’s versatility as a transcriptional regulator responsive to epigenetic cues shaped by metabolic state—and its pathogenic contribution when aberrantly activated.

From a clinical perspective, these findings pave the way for developing targeted therapies that disrupt the histone lactylation-GLI3-SERPINE1 axis. Given the absence of FDA-approved pharmacologic treatments specifically for AAA, interventions that modulate macrophage polarization or inhibit exosomal pathways could transform patient management. Such therapeutic innovations might reduce surgical interventions and improve outcomes for individuals with aneurysms detected at an earlier stage.

Furthermore, the identification of histone lactylation as a modifiable post-translational modification opens the door to a broader understanding of how metabolic dysregulation influences chronic inflammatory diseases outside AAA. This epigenetic mechanism may be relevant to atherosclerosis, fibrosis, and other cardiovascular pathologies where macrophage activation status is a determining factor.

The study’s multidisciplinary approach—intersecting vascular biology, immunology, metabolism, and epigenetics—exemplifies the future of biomedical research aimed at unraveling complex disease mechanisms. By integrating molecular biology with systems-level analysis, the investigators provide a comprehensive framework for understanding how cellular and microenvironmental factors converge to accelerate AAA progression.

Looking ahead, further research is warranted to explore the translational potential of these findings in human patients. Extensive validation of SERPINE1-containing exosomes as circulating biomarkers could facilitate earlier diagnosis and risk stratification. Moreover, designing small molecule inhibitors or RNA-based therapies targeting key nodes within this pathway may offer promising clinical utility.

In conclusion, this study represents a seminal contribution to the field of vascular disease research, illuminating a novel epigenetic-metabolic axis that governs macrophage behavior and intercellular communication through exosomes in abdominal aortic aneurysm pathology. By deciphering the molecular underpinnings of aneurysm progression, the work not only enriches our fundamental biological knowledge but also charts a course toward innovative diagnostics and therapeutic strategies aimed at curbing this silent but deadly disease.

Subject of Research:
Article Title:
Article References:
Yuan, K., Liu, J., Chen, G. et al. Histone lactylation-induced GLI3 activation drives macrophage M1 polarization and exosomal SERPINE1 release in abdominal aortic aneurysm progression. Cell Death Discov. 11, 523 (2025). https://doi.org/10.1038/s41420-025-02748-7
Image Credits: AI Generated
DOI: 10 November 2025

Discovered only in 2019, lysine lactylation initially gained recognition as a histone modification linked to epigenetic regulation. Histones, the protein spools around which DNA wraps, are subject to various chemical modifications that dynamically alter chromatin structure and transcriptional activity. Kla on key histone sites such as H3K18la, H3K23la, and H4K12la has been implicated in crucial biological processes including early embryogenesis, immune modulation, metabolic reprogramming in cancer, and tumor progression. However, the new review reveals that Kla’s scope extends far beyond chromatin, modifying a wide spectrum of non-histone proteins, thereby orchestrating multifaceted cellular functions.

One of the major leaps this review achieves is integrating mechanistic insights about the enzymes involved in Kla. The authors present updated information on ‘writers’ that install Kla marks, ‘erasers’ that remove them, and ‘readers’ that recognize lactylated lysines, drawing parallels yet highlighting distinctions between histone and non-histone substrates. Intriguingly, the modification can arise through enzymatic pathways involving L-lactyl-CoA synthetases like ACSS2 and GTPSCS, or via non-enzymatic methods in metabolically active environments. This dual mode of Kla regulation underscores its adaptability as a metabolic sensor and effector.

Non-histone protein lactylation is emerging as a powerful regulator of cellular processes far removed from canonical epigenetics. For instance, lactylation of Vps34 plays a pivotal role in autophagy, a fundamental cellular housekeeping pathway. Similarly, Tau-Kla influences ferroptosis, a form of regulated cell death linked to neurodegenerative diseases. Immune signaling pathways are also modulated via lactylation of proteins such as RIG-I and BCAP, implicating Kla in antiviral defense and inflammatory responses. This broadened landscape reveals Kla as a nexus connecting metabolic states to diverse cell functions.

The review also outlines the functional and pathological relevance of Kla in cancer biology. Histone Kla promotes tumor angiogenesis through epigenetic activation of key players like HIF1-ɑ and Vegf, aiding tumor vascularization. Beyond histones, non-histone lactylation of proteins such as YY1 and Sema3A influences the tumor microenvironment by regulating FGF2 and HIF1-ɑ, respectively. Moreover, Kla on enzymes like LDHA modulates glycolytic flux, directly impacting cancer cell proliferation. These insights open new avenues for targeting metabolic-epigenetic crosstalk in oncology.

Importantly, the authors shed light on Kla’s integral role in tumor immunity. Histone Kla can modulate T cell responses, shaping immune surveillance. Meanwhile, lactylation of ALKBH5, CBX3, and the innate immune sensor RIG-I fine-tunes expression of immune checkpoint molecules and inflammation regulators like IFN-R, CD47, and NLRP3. This highlights Kla’s potential as a lever for immunotherapeutic strategies, a rapidly evolving frontier in cancer treatment.

Advancing technical capabilities have propelled Kla research to new heights. The review emphasizes cutting-edge detection techniques such as CUT&Tag and tandem mass spectrometry that afford site-specific mapping of lactylation marks with unprecedented resolution. These innovations enable precise dissection of Kla landscapes in physiological and pathological contexts, facilitating the development of Kla-targeted diagnostics and therapeutics.

Moreover, the review situates Kla within a broader pathological spectrum, linking it to cardiovascular disease, sepsis, and neurodegeneration. For instance, the association of histone H3K18la with macrophage polarization and pulmonary hypertension suggests Kla’s involvement in inflammatory and vascular disorders. This expansive disease relevance positions Kla as a critical node in metabolic signaling with far-reaching clinical implications.

Notably, Prof. Du and Dr. Peng emphasize that Kla represents an underappreciated epigenetic and post-translational modification axis. Their comprehensive synthesis underscores the need to bridge previous histone-centric approaches with emerging evidence of non-histone protein lactylation. Understanding this axis could illuminate key mechanisms whereby metabolic dysregulation rewires cellular behavior, advancing both fundamental biology and translational medicine.

Ultimately, this authoritative review represents a call to action for the scientific community. By systematically integrating knowledge of histone and non-histone lactylation, the authors unveil promising therapeutic targets across cancer, immunity, and metabolic disorders. The Kla axis is poised to become a vibrant area of research, revolutionizing our grasp of how metabolic cues sculpt the cellular proteome and epigenome to influence health and disease.

With metabolism at the helm of cellular regulation, lysine lactylation emerges as a master regulator, deftly linking metabolic environments to intricate biological outcomes. As Kla research gains momentum, its clinical translation offers hope for new interventions tailored to the metabolic landscapes of complex diseases. This review by Du and Peng not only synthesizes the current state of the field but establishes a roadmap for the future, heralding a new era in molecular biomedicine where metabolism and epigenetics converge through lactylation.

Subject of Research: Lysine lactylation (Kla) in histone and non-histone proteins: molecular mechanisms, biological functions, and therapeutic potential

Article Title: Histone and non-histone lactylation: molecular mechanisms, biological functions, diseases, and therapeutic targets

News Publication Date: 9-Jun-2025

Web References: DOI: 10.1186/s43556-025-00275-6

Image Credits: Juan Du